Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells

Exclusion Criteria

• •1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids);
• •2. Patients who take chemotherapy within 1 month prior to treatment;
• •3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment;
• •4. Patients with T lymphoma and NK cell lymphoma;
• •5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.;
• •6. Seriously uncontrollable infected patients;
• •7. Patients who are allergic to the biological agents in this treatment;
• •8. Patients with organ transplantation or organ failure;
• •9. Subjects with severe cardiovascular disease and severe renal failure;
• •10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation;
• •11. Patients with active infection or fever;
• •12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction;
• •13. Subjects with pregnancy or during the lactating period.